ArticleHeliyon2024
High sensitivity chemiluminescence enzyme immunoassay for detecting staphylococcal enterotoxin C1 and its application in multi-matrices.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcal enterotoxins (SEs) serve as the primary cause of staphylococcal food poisoning and other foodborne intoxications. Among them, staphylococcal enterotoxin C (SEC) has the highest prevalence in dairy products, leading to multiple outbreaks all around the world. Thus, it is of great significance to develop a highly sensitive, highly specific and easy to operate chemiluminescent sandwich enzyme immunoassay (CLEIA) for detecting staphylococcal enterotoxin C (SEC1). We selected two pairs of anti-SEC1 monoclonal antibodies (mAbs) (SEC1-G8 and SEC1-C4), and a chemiluminescent sandwich enzyme immunoassay (CLEIA) was constructed. This approach can detect SEC1 within a concentration spectrum of 3.2-4000 pg/mL, with the detection limit being 2.1 pg/mL. At three concentrations (3.2, 20, and 400 pg/mL), both the intra- and inter-assay coefficient variations were coming in at 6.31 % and 11.2 % respectively. No cross-reaction was noticed in the SEA, SEB, and SED tests. SEC1 was successfully detected by employing the CLEIA method in spiked matrices and commercial samples, and the average recovery rate ranges from 81.6 % to 108.1 %. Therefore, the highly sensitive, SEC1- specific, and easy-to-operate CLEIA could be a useful tool in the near future for quantifying SEC1 in public health and food safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.